ASCO 2025 | Olaparib and durvalumab combination therapy for advanced endometrial cancer
Shannon Westin, MD, FASCO, The University of Texas MD Anderson Cancer Center, and GOG-F, Houston, TX, discusses the combination of checkpoint inhibitor durvalumab and PARP inhibitor olaparib as a treatment strategy for patients with advanced and recurrent mismatch-repair proficient (pMMR) endometrial cancer. The DUO-E study (NCT04269200) is currently testing the combination therapy with the aim of improving progression-free survival (PFS) and overall outcomes for patients with pMMR endometrial cancer who don’t respond to single-agent immunotherapy. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Sure, I mean, I think we’ve got some really interesting mechanistic data that the combination of olaparib and PD-L1 inhibitors, and even maybe PD-1 checkpoint inhibitors, could potentially be additive and maybe even synergistic, right? Because when we utilize a PARP inhibitor, we create more DNA damage, we create neoantigens, and that allows the immune system to find the cancer and hopefully clear it...
Sure, I mean, I think we’ve got some really interesting mechanistic data that the combination of olaparib and PD-L1 inhibitors, and even maybe PD-1 checkpoint inhibitors, could potentially be additive and maybe even synergistic, right? Because when we utilize a PARP inhibitor, we create more DNA damage, we create neoantigens, and that allows the immune system to find the cancer and hopefully clear it. So we’re starting to build that story around how that mechanism of action may actually be true. We are hoping that once survival data are available for the DUO-E study, that we will be able to offer the combination of olaparib and durvalumab to our patients with advanced and recurrent mismatch repair proficient endometrial cancer. Because I think the use of checkpoint in mismatch repair deficient endometrial cancer is a clear win and it’s hard to improve upon that at least right now. But I think the addition of PARP in this space to mismatch repair proficient can really help us potentially improve progression-free survival and you know duration of response and overall improvement in outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
